Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.
Amir Fathi, MD
Advertisement
Amir Fathi, MD, is program director of the Center for Leukemia at Massachusetts General Hospital; as well as an associate professor of medicine at Harvard Medical School
Articles by Amir Fathi, MD
Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.
Advertisement
Latest Updated Articles
Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AMLPublished: June 13th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5